- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Glenmark Pharmaceuticals Ltd (GLEN)
Glenmark Pharmaceuticals Ltd stock price live, this page displays NSE GLEN stock exchange data. View the GLEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Glenmark Pharmaceuticals Ltd real time stock price chart below.
What Is the Glenmark Pharmaceuticals Ltd Stock Price Today?
The Glenmark Pharmaceuticals Ltd stock price today is 2,225.00.
What Is the Stock Symbol for Glenmark Pharmaceuticals Ltd?
The stock symbol for Glenmark Pharmaceuticals Ltd is "GLEN."
What Stock Exchange Does Glenmark Pharmaceuticals Ltd Trade On?
Glenmark Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Glenmark Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Glenmark Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLEN quote. (ISIN: INE935A01035)
What Is the Glenmark Pharmaceuticals Ltd Stock Price Today?
The Glenmark Pharmaceuticals Ltd stock price today is 2,225.00.
What Is the Stock Symbol for Glenmark Pharmaceuticals Ltd?
The stock symbol for Glenmark Pharmaceuticals Ltd is "GLEN."
What Stock Exchange Does Glenmark Pharmaceuticals Ltd Trade On?
Glenmark Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Glenmark Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Glenmark Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLEN quote. (ISIN: INE935A01035)
Currency in INR
2,225.00
-5.00(-0.22%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,200.00
2,244.00
52 wk Range
1,792.60
2,474.00
GLEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,200.002,244.00
52 wk Range
1,792.602,474.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.22%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.22%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GLEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
2,504.09
Upside
+12.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2,504.09
(+12.54% Upside)
Glenmark Pharmaceuticals Ltd Earnings Call Summary for Q1/2027
- Glenmark posted Q1 FY2027 EPS of $17.11 vs $17.10 est.; revenue rose 23.1% YoY to $40.18B, beating $39.49B forecast by 1.75%.
- Growth was broad-based: North America up 41.1%, emerging markets up 27.7%, Europe up 11.9%, India formulations up 15.5% YoY.
- Management maintained FY2027 operating margin guidance at 21-22% despite API cost pressures; R&D spend held at 7-8% of revenue.
- Company expects 2-3 U.S. respiratory approvals in H2 FY2027; targeting oncology expansion with AUMOLERTINIB and other pipeline assets.
- Shares fell 0.32% to $2,226.80 post-results; Europe growth to accelerate as branded products rise from 30% to 60% of regional revenue over 5 years.
Last Updated: 2026/08/03, 07:08
Read Full TranscriptEarnings
Latest Release
Jul 31, 2026
EPS / Forecast
17,11 / 17,10
Revenue / Forecast
40,18B / 39,49B
Compare GLEN to Peers and Sector
Metrics to compare | GLEN | Peers Peers - average of corresponding metrics from companies closely matching GLEN: AUROPHARMA, MANKIND, ALKEM, ZYDUSLIFE, SUNPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLENPeersSector |
|---|---|---|---|---|
P/E Ratio | 35.0x | 29.8x | −0.4x | |
PEG Ratio | 0.25 | 1.10 | 0.00 | |
Price/Book | 6.0x | 4.5x | 2.6x | |
Price / LTM Sales | 3.5x | 4.1x | 3.0x | |
Upside (Analyst Target) | 16.1% | 5.8% | 54.3% | |
Fair Value Upside | Unlock | 1.7% | 8.4% | Unlock |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company’s pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Glenmark Pharma (GLEN) Stock Price Today?
The Glenmark Pharma stock price today is 2 225,00 INR.
What Stock Exchange Does Glenmark Pharma Trade On?
Glenmark Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Glenmark Pharma?
The stock symbol for Glenmark Pharma is "GLEN."
Does Glenmark Pharma Pay Dividends? What’s The Current Dividend Yield?
The Glenmark Pharma dividend yield is 0.22%.
What Is the Glenmark Pharma Market Cap?
As of today, Glenmark Pharma market cap is 625,64B INR.
What Is Glenmark Pharma's Earnings Per Share (TTM)?
The Glenmark Pharma EPS (TTM) is 63,69.
When Is the Next Glenmark Pharma Earnings Date?
Glenmark Pharma will release its next earnings report on Nov 06, 2026.
From a Technical Analysis Perspective, Is GLEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Glenmark Pharma Stock Split?
Glenmark Pharma has split 4 times.
How Many Employees Does Glenmark Pharma Have?
Glenmark Pharma has 15800 employees.
What is the current trading status of Glenmark Pharma (GLEN)?
As of Aug 04, 2026, Glenmark Pharma (GLEN) is trading at a price of 2 225,00 INR, with a previous close of 2 230,00 INR. The stock has fluctuated within a day range of 2 200,00 INR to 2 244,00 INR, while its 52-week range spans from 1 792,60 INR to 2 474,00 INR.
What Is Glenmark Pharma (GLEN) Price Target According to Analysts?
The average 12-month price target for Glenmark Pharma is 2 504,09 INR, with a high estimate of 2750 INR and a low estimate of 2100 INR. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +12,54% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.